Loading...
XNAS
CAPR
Market cap460mUSD
Oct 09, Last price  
7.75USD
1D
-1.11%
1Q
-62.76%
Jan 2017
-69.89%
IPO
-98.22%
Name

Capricor Therapeutics Inc

Chart & performance

D1W1MN
XNAS:CAPR chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
24.45%
Rev. gr., 5y
85.83%
Revenues
0
-100.00%
380,835101,4000001,355,000195,500503,2334,167,0003,776,0003,190,0002,666,0001,671,0001,005,028310,250244,8982,551,46925,178,06622,270,4650
Net income
-105m
L+159.58%
-2,581,972-10,303,000-13,132,000-7,872,000-6,031,000-4,885,000-1,893,000-8,892,000-6,217,000-12,857,000-18,807,0002,431,000-15,191,000-7,641,817-13,657,028-20,022,520-29,019,532-22,287,542-40,467,186-105,043,946
CFO
-70m
L+74.55%
-55,597-5,372,617-10,640,044-5,795,494-4,318,264-4,649,292-2,186,681-6,144,000958,562-10,817,286-15,801,620-14,230,879-13,862,441-6,821,501-10,054,810-16,809,3244,916,637-25,596,545-39,995,742-69,811,261

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Key people

Linda Marban
President, Chief Executive Officer, Director · since 2014
Anthony Bergmann
Chief Financial Officer, Principal Accounting Officer · since 2018
Karen G. Krasney
Executive Vice President, General Counsel · since 2013
Thomas Lyle Copmann
Vice President - Regulatory Affairs and Drug Development · since 2015
Houman Hemmati
Vice President - Medical & Clinical Development, New Therapies · since 2015
Luis Rodriguez-Borlado
Vice President - Regenerative Therapies · since 2015
Deborah Ascheim
Chief Medical Officer · since 2015
Joshua Kazam
Director · since 2012
Frank I. Litvack
Independent Executive Chairman of the Board · since 2013
Earl M. Collier
Independent Director · since 2013
Louis J. Grasmick
Independent Director · since 2013
Louis Manzo
Independent Director · since 2013
URL
https://capricor.com/
IPO date
Jun 04, 2002
Employees
74
Domiciled in
US
Incorporated in
US
Legal address
c/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street
Wilmington, DE 19801
US
Headquarters
8840 Wilshire Boulevard; 2nd Floor
Beverly Hills, CA 90211
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT